Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke.
Acticor Biotech has raised $8.7M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2024.
Acticor Biotech's investors include GO CAPITAL, Mirae Asset, Karista, Newton Biocapital, UI Investissement.
Acticor Biotech is headquartered in Paris, France.
Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke.
Acticor Biotech is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Acticor Biotech — Funding & Investors." VCBacked, March 15, 2024, https://www.vcbacked.co/company/acticor-biotech. Accessed September 8, 2026.
VCBacked. (2024). Acticor Biotech — Funding & Investors. Retrieved September 8, 2026, from https://www.vcbacked.co/company/acticor-biotech
{{cite web |title=Acticor Biotech — Funding & Investors |url=https://www.vcbacked.co/company/acticor-biotech |website=VCBacked |access-date=September 8, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated